HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
A2302 Anti-VEGFC Anti-VEGFC is a fully human monoclonal antibody targeting the human vascular endothelial growth factor C (VEGFC or Flt4 ligand) with potential antiangiogenic activity and lymphangiogenesis. It also prevent metastasis. MW :145.5 KD. Aug 10 2023
A2303 Anti-VEGFB Anti-VEGFB (CSL346) is an antibody targeting VEGFA. MW:150 KD. Aug 10 2023
A2559 Galiximab (Anti-CD28L / CD80) Galiximab (Anti-CD28L/CD80) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody targeting against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma. MW:145.5 KD. Aug 10 2023
A2560 Anti-CD28 Anti-CD28 (FR104) is an antibody targeting CD28. MW:145.5 KD. Aug 10 2023
A2305 Ranibizumab (Anti-VEGFA) Ranibizumab (Anti-VEGFA) is a recombinant humanized IgG1 monoclonal antibody fragment that inhibits (VEGF-A) and degrades angiogenesis throughout the body and in the eye also interrupts the interaction of VEGF with its receptors, and thus prevents the subsequent growth of new blood vessels. Aug 10 2023
A2561 Ocrelizumab (Anti-CD20) Ocrelizumab (Anti-CD20) is a recombinant humanized monoclonal IgG1 antibody that selectively targets CD20 antigen present on B-cells. It is used to treat relapsing remitting multiple sclerosis. MW:145.5 KD. Aug 10 2023
A2306 otlertuzumab (Anti-TSPAN26 / CD37) Otlertuzumab (Anti-TSPAN26 / CD37) is a humanized monoclonal antibody and anti-CD37 protein therapeutic. It is a potent monospecific protein used in treatments of refractory follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), or Waldenström's macroglobulinaemia (WM) Aug 10 2023
A2562 Siplizumab (Anti-CD2) Siplizumab (Anti-CD2) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells. MW:145.5 KD. Aug 10 2023
A2307 Tezepelumab (Anti-TSLP) Tezepelumab (Anti-TSLP) is a potent human IgG2 monoclonal antibody that inhibits the binding of TSLP to the TSLP receptor, and also has potent efficacy and mechanism in asthma. Aug 10 2023
A2563 Tafasitamab (Anti-CD19) Tafasitamab (Anti-CD19) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigen CD19. It is used in combination with allogeneic NK cell therapy in treatment of B-cell non-Hodgkin's lymphoma. MW:145.5 KD. Aug 10 2023
A2308 Anti-TSHR Anti-TSHR are unconjugated polyclonal antibodies derived from rabbi. Anti-TSHR are pathophysiologic, and also increases their significance in the diagnosis of autoimmune thyroid diseases and Graves' disease. Aug 10 2023
A2564 Inebilizumab (Anti-CD19) Inebilizumab (Anti-CD19) is an monoclonal antibody targeting CD19 antigen present on B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research. MW:145.5 KD. Aug 10 2023
A2309 Flanvotumab (Anti-TRP1 / TYRP1) Flanvotumab (Anti-TRP1 / TYRP1) is a monoclonal antibody directed against the melanosomal membrane protein gp75 (or Tyrosinase-Related Protein 1 (TRP1)) with potential immunostimulatory and antineoplastic activities. MW: 145.5 kD. Aug 10 2023
A2565 Anti-CD163 Anti-CD163 (OR2805) is a human immunoglobulin G1 (IgG1) monoclonal antibody targeting CD163 (scavenger receptor cysteine-rich type 1 protein M130), with potential immunomodulating and antineoplastic activities. It targets and binds to CD163 expressed on immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment (TME), and prevents the binding of CD163 to its ligands. MW:145.5 KD. Aug 10 2023
A2566 Atibuclimab (Anti-CD14) Atibuclimab (Anti-CD14) is a chimeric monoclonal antibody targeting CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. MW:145.5 KD. Aug 10 2023
A2311 Anti-TrkA / NTRK1 Anti-TrkA / NTRK1 is a non-conjugated, rabbit-derived monoclonal antibody targeting TrkA. MW : 145.5 KD. Aug 10 2023
A2312 Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) is a humanized monoclonal antibody that specifically recognizes and binds to CD70 molecular. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells and shows inhibitory efficacy against Burkitt’s lymphoma. MW : 150 kDa. Aug 10 2023
A2568 Mogamulizumab (Anti-CCR4 / CD194) Mogamulizumab (Anti-CCR4 / CD194) is a defucosylated humanized recombinant monoclonal antibody targeting CCR4. Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL). MW:145.5 KD. Aug 10 2023
A2313 Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) is a humanized immunoglobulin monoclonal antibody that targets TNFSF5. MW : 150 kDa. Aug 10 2023
A2569 Plozalizumab (Anti-CCR2 / CD192) Plozalizumab (Anti-CCR2 / CD192) is a specific humanized monoclonal antibody targeting CCR2. Plozalizumab can be used for malignant melanoma research. MW:145.5 KD. Aug 10 2023